BIO.B Stock Forecast 2025-2026
Distance to BIO.B Price Targets
BIO.B Price Momentum
10 Quality Stocks Worth Considering Now
Researching Bio-Rad (BIO.B) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BIO.B and similar high-potential opportunities.
Latest BIO.B Stock Price Targets & Analyst Predictions
BIO.B has shown a year-to-date change of -18.4% and a 1-year change of -20.0%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for BIO.B. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BIO.B Analyst Ratings
BIO.B Price Target Range
Latest BIO.B Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BIO.B.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 12, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $345.00 |
| Jan 14, 2025 | RBC Capital | Conor McNamara | Outperform | Reiterates | $481.00 |
| Dec 9, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $481.00 |
| Oct 31, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $469.00 |
| Oct 31, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $450.00 |
| Oct 1, 2024 | Citigroup | Patrick Donnelly | Buy | Upgrade | $400.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Equal-Weight | Initiates | $340.00 |
| Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $401.00 |
| Aug 2, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $401.00 |
| Aug 2, 2024 | Citigroup | Patrick Donnelly | Neutral | Maintains | $350.00 |
| Jun 3, 2024 | Jefferies | Hold | Assumes | $315.00 | |
| May 8, 2024 | UBS | Dan Leonard | Buy | Maintains | $385.00 |
| Apr 3, 2024 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $365.00 |
| Feb 16, 2024 | UBS | Dan Leonard | Buy | Maintains | $420.00 |
| Feb 16, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $480.00 |
| Dec 7, 2023 | UBS | Dan Leonard | Buy | Initiates | $395.00 |
| Aug 7, 2023 | Wells Fargo | Dan Leonard | Overweight | Maintains | $525.00 |
| Aug 4, 2023 | RBC Capital | Conor McNamara | Outperform | Maintains | $524.00 |
| Aug 4, 2023 | Credit Suisse | Dan Leonard | Outperform | Maintains | $550.00 |
| Jun 16, 2023 | Wells Fargo | Dan Leonard | Overweight | Initiates | $550.00 |
Bio-Rad Laboratories, Inc. (BIO.B) Competitors
The following stocks are similar to Bio-Rad based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bio-Rad Laboratories, Inc. (BIO.B) Financial Data
Bio-Rad Laboratories, Inc. has a market capitalization of $7.02B with a P/E ratio of -4.1x. The company generates $2.57B in trailing twelve-month revenue with a -71.9% profit margin.
Revenue growth is -2.0% quarter-over-quarter, while maintaining an operating margin of +8.7% and return on equity of -24.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Bio-Rad Laboratories, Inc. (BIO.B) Business Model
About Bio-Rad Laboratories, Inc.
Develops advanced analytical and diagnostic technologies.
Bio-Rad Laboratories generates revenue through the sale of innovative products and systems used in life sciences and clinical diagnostics. Their diverse product range includes PCR instruments, chromatography systems, and immunoassays, catering to various sectors like healthcare, research, and food safety.
Established in 1952, Bio-Rad is recognized for its commitment to reliable scientific advancements, which has positioned it as a trusted partner in both scientific exploration and healthcare enhancement globally.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,700
CEO
Mr. Norman D. Schwartz
Country
United States
IPO Year
1999
Website
www.bio-rad.comBio-Rad Laboratories, Inc. (BIO.B) Latest News & Analysis
Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit
4 months agoBio-Rad Laboratories reported Q3 profit exceeding Wall Street estimates, driven by increased demand for analytical tools from biotech clients and steady growth in clinical diagnostics sales.
Bio-Rad's profit exceeding estimates signals strong demand in biotech and stable sales in diagnostics, indicating potential growth and profitability, which can boost investor confidence and stock value.
Bio-Rad Laboratories has lowered its annual revenue growth forecast due to weak demand for clinical diagnostics products from biotech clients.
Bio-Rad's lowered revenue forecast indicates declining demand in a key sector, potentially signaling broader industry challenges and impacting investor confidence and stock performance.
Bio Rad Laboratories maintained its 2024 sales growth forecast despite ongoing weak spending from biotech firms and sluggish demand in China.
Bio Rad's reaffirmed sales growth forecast amidst weak biotech spending and sluggish demand in China signals potential revenue challenges, impacting stock performance and investor outlook.
Bio-Rad Laboratories reduced its annual revenue growth forecast due to uncertainties in the biopharma sector, causing shares to drop approximately 11% in after-hours trading.
Lowered revenue growth forecasts indicate potential challenges for Bio-Rad, which can affect investor confidence and stock performance, leading to significant declines in share prices.
Investors should monitor health care stocks with consistent earnings growth and strong performance metrics, as they are identified as top candidates in the sector.
Earnings growth in health care stocks signals stability and potential for returns, making them attractive for investment amidst market fluctuations.
Bio-Rad (BIO) received regulatory approval, aligning with its strategy to enhance its presence in the U.S. transfusion medicine market.
Bio-Rad's regulatory approval enhances its position in the U.S. transfusion medicine market, potentially boosting revenue and market share, which can positively impact stock performance.
Frequently Asked Questions About BIO.B Stock
What is Bio-Rad Laboratories, Inc.'s (BIO.B) stock forecast for 2025?
Analyst forecasts for Bio-Rad Laboratories, Inc. (BIO.B) are not currently available. The stock is trading at $265.82.
Is BIO.B stock a good investment in 2025?
Analyst ratings for BIO.B are not currently available. The stock is currently trading at $265.82. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BIO.B stock?
Price predictions from Wall Street analysts for BIO.B are not currently available. The stock is trading at $265.82.
What is Bio-Rad Laboratories, Inc.'s business model?
Bio-Rad Laboratories generates revenue through the sale of innovative products and systems used in life sciences and clinical diagnostics. Their diverse product range includes PCR instruments, chromatography systems, and immunoassays, catering to various sectors like healthcare, research, and food safety.
What is the highest forecasted price for BIO.B Bio-Rad Laboratories, Inc.?
Price targets from Wall Street analysts for BIO.B are not currently available. The stock is trading at $265.82.
What is the lowest forecasted price for BIO.B Bio-Rad Laboratories, Inc.?
Price targets from Wall Street analysts for BIO.B are not currently available. The stock is trading at $265.82.
What is the overall BIO.B consensus from analysts for Bio-Rad Laboratories, Inc.?
Analyst ratings for BIO.B are not currently available. The stock is trading at $265.82.
How accurate are BIO.B stock price projections?
Stock price projections, including those for Bio-Rad Laboratories, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
